Full Text View
Tabular View
No Study Results Posted
Related Studies
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
This study is currently recruiting participants.
Study NCT00684411   Information provided by Dana-Farber Cancer Institute
First Received: May 22, 2008   Last Updated: October 2, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
T Cell Non-Hodgkin Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Imatinib mesylate
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services